使用基于费里的蛋白提供抗疟疾药物:迈向开发针对疟疾的智能治疗方法的一步
Shruti Bhatt1, Subrata Dasgupta2, Chiging Tupe3,4
1Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, New Delhi 110021, India.
Biochemistry
|July 8, 2024
概括
这项研究探讨了使用费里蛋白来输送抗疟疾药物. 将药物封装在费里丁中显示出对疟疾寄生虫的有效性,提供了一个有前途的新输送系统,具有高选择性和很少副作用.
科学领域:
- 生物技术和纳米医学
- 寄生虫学和热带疾病
背景情况:
- 蛋白质在生物技术和治疗中得到了广泛的应用,特别是在疫苗开发 (例如,COVID-19) 和药物输送方面.
- 基于费里的子是领先的药物输送系统,因为它们的稳定性,易于生产和无毒性,通常用于抗癌药物和对比剂.
- 在这项研究之前,费里丁对抗疟疾药物输送的潜力仍然未被探索.
研究的目的:
- 调查基于费里的蛋白作为抗疟疾药物的新型输送系统的有效性.
- 探索马ferritin中的抗疟疾药物的封装,结合和加载机制.
- 为了评估药物 - 费里丁纳米结合物的治疗潜力,对抗 *Plasmodium* 寄生虫.
主要方法:
- 封装各种抗疟疾药物到马铁素中.
- 使用实验和计算技术验证药物结合和加载.
- 计算对接和分子动力学模拟以确定费里结构内的药物结合点.
- 药物-费里纳米合物的体外疗效测试在 *Plasmodium* 寄生虫上.
主要成果:
- 抗疟疾药物成功地被纳入费里丁,而不会损害其结构完整性.
- 计算分析精确地确定了费里细胞内的药物结合位置.
- 开发的药物-费里丁纳米结合物在消灭*Plasmodium*寄生虫方面表现出显著的有效性.
结论:
- 基于费里的载体系统显示出在推进抗疟疾药物输送方面有很大的前景.
- 这种方法为治疗疟疾提供了一种高度选择性和潜在的低副作用的方法.
- 这些发现为开发用于传染病治疗的新型纳米结合物铺平了道路.
相关概念视频
01:28The Early Endosome: Endocytosis of Transferrin
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...